Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Terminated 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 4Gastrointestinal 1

Conditions

Colorectal Neoplasms 90Carcinoma, Hepatocellular 29Neoplasm Metastasis 18Neoplasms 16Gastrointestinal Stromal Tumors 13Colonic Neoplasms 13Rectal Neoplasms 12Sarcoma 6Glioblastoma 6Stomach Neoplasms 5Sarcoma, Ewing 5Ovarian Neoplasms 5Osteosarcoma 5Melanoma 5Liver Neoplasms 5Cholangiocarcinoma 5Adenocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Leukemia, Myeloid, Acute 3Colorectal Cancer Metastatic 3Carcinoma, Transitional Cell 3Carcinoma 3Advanced Colorectal Cancer 3Thyroid Neoplasms 2

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × regorafenib × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated
89 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02773524 2022-01-13

INTEGRATEIIa

Australasian Gastro-Intestinal Trials Group

Phase 3 Unknown
250 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT01929616 2019-06-25

RegARd-C

Jules Bordet Institute

Phase 2 Completed
141 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02119676 2018-02-13

Study of Ruxolitinib in Colorectal Cancer Patients

Incyte Corporation

Phase 2 Terminated
396 enrolled 15 charts
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡